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Melanoma is a tumour of transformed melanocytes, which are
originally derived from the embryonic neural crest. It is unknown
to what extent the programs that regulate neural crest development
interact with mutations in the BRAF oncogene, which is the most
commonlymutated gene inhumanmelanoma1.Wehaveused zebra-
fish embryos to identify the initiating transcriptional events that
occur on activation of human BRAF(V600E) (which encodes an
amino acid substitutionmutant of BRAF) in theneural crest lineage.
Zebrafish embryos that are transgenic for mitfa:BRAF(V600E) and
lack p53 (also known as tp53) have a gene signature that is enriched
for markers of multipotent neural crest cells, and neural crest pro-
genitors from these embryos fail to terminally differentiate. To
determine whether these early transcriptional events are important
formelanomapathogenesis, we performed a chemical genetic screen
to identify small-molecule suppressors of the neural crest lineage,
which were then tested for their effects on melanoma. One class of
compound, inhibitors of dihydroorotate dehydrogenase (DHODH),
for example leflunomide, led to an almost complete abrogation of
neural crest development in zebrafish and to a reduction in the self-
renewal of mammalian neural crest stem cells. Leflunomide exerts
these effects by inhibiting the transcriptional elongation of genes
that are required for neural crest development and melanoma
growth.Whenused alone or in combinationwith a specific inhibitor
of the BRAF(V600E) oncogene,DHODH inhibition led to amarked
decrease in melanoma growth both in vitro and in mouse xenograft
studies. Taken together, these studies highlight developmental path-
ways in neural crest cells that have a direct bearing on melanoma
formation.
In melanoma, it is unknown to what extent BRAF(V600E) muta-
tions depend on transcriptional programs that are present in the
developmental lineage of tumour initiation. These programs may be
therapeutic targets when combined with BRAF(V600E) inhibition.
We have used zebrafish embryos to identify small-molecule suppres-
sors of neural crest progenitors that give rise tomelanoma. Transgenic
zebrafish expressing human BRAF(V600E) under the melanocyte-
specific mitfa promoter, Tg(mitfa:BRAF(V600E)), develop melanoma
at 4–12 months of age when crossed with p532/2 mutant zebrafish,
Tg(mitfa:BRAF(V600E)); p532/2 (Fig. 1a). Because themitfa promoter
drives the expression of BRAF(V600E) from 16h after fertilization
(a time point that overlaps with the expression of embryonic neural
crest markers such as sox10), events that occur early in embryogenesis
are analogous to those that occur at tumour initiation. To gain
insight into these initiating events, we compared the gene expression
profiles of Tg(mitfa:BRAF(V600E)); p532/2 embryos with those of
Tg(mitfa:BRAF(V600E)); p532/2melanomas by using gene set enrich-
ment analysis (Fig. 1b). This approach uncovered a signature of 123
overlapping genes, which is enriched for markers of embryonic neural
crest progenitors (crestin, sox10 and ednrb (also known as ednrb1))
andmelanocytes (tyr and dct) (see Supplementary Table 1 for full gene
sets). The overlapping gene signature is similar to the signature of a
multipotent neural crest progenitor, suggesting that the melanomas
have adopted this cell fate.
We analysed alterations in embryonic neural crest development by
using in situ hybridization. At 24 h post fertilization, Tg(mitfa:BRAF
(V600E)); p532/2 embryos show an abnormal expansion in the num-
ber of crestin1 progenitors, together with an increase in other markers
from the 123 gene signature such as spry4 and rab3il1 (Supplementary
Fig. 1). By 72 h post fertilization, crestin persists aberrantly in the head,
tail and dorsal epidermis only in Tg(mitfa:BRAF(V600E)); p532/2
embryos but not in embryos with either single mutation (Supplemen-
tary Fig. 2a). The gene encoding Crestin is zebrafish specific2 and is
normally downregulated after the terminal differentiation of neural
crest progenitors3. Our finding therefore suggests that activated
BRAF(V600E) promotes the maintenance of multipotency in neural
crest progenitors, which become expanded during tumorigenesis. In
adult Tg(mitfa:BRAF(V600E)); p532/2 melanomas, almost all tumour
cells, but no normal cells, were positive for crestin (Fig. 1c). Only 10–
15% of the melanoma cells were pigmented (Supplementary Fig. 2b),
which is consistent with the concept that adult zebrafish melanomas
retain a progenitor-like state. A human melanoma tissue array yielded
similar results: 52 out of 70 of themelanomas on the array (74.3%)were
positive for the neural crest progenitor gene ednrb, but only 9 of 70
(12.9%) were positive for the melanocyte lineage marker dct
(SupplementaryFig. 3), in agreementwith the finding thatmosthuman
melanomas express the neural crest marker sox10 (ref. 4). These data
indicate that the majority of humanmelanomas reflect events that lead
to the maintenance of a neural crest progenitor phenotype5.
We proposed that chemical suppressors of neural crest progenitors
would be useful for treating melanoma. We screened 2,000 chemicals
to identify compounds that inhibit the crestin1 lineage during embryo-
genesis. Most chemicals (90%) had a minimal effect or were toxic
(Supplementary Fig. 4). NSC210627, amolecule of unknown function,
strongly abrogated the expression of crestin (Fig. 2a, centre and left).
The chemoinformatic algorithm DiscoveryGate6 revealed similarity
betweenNSC210627 andbrequinar (Supplementary Fig. 5), an inhibitor
of DHODH7. NSC210627 inhibited DHODH activity in vitro (Sup-
plementary Fig. 6). Leflunomide, aDHODHinhibitor that is structurally
distinct from NSC210627 (ref. 8), phenocopied NSC210627 (Fig. 2a,
right) and was used for further studies because of its availability.
Weexaminedneural crest derivatives affectedby leflunomide.Treated
zebrafish embryos were devoid of pigmented melanocytes at 36–48h
post fertilization (Fig. 2b) and iridophores at 72h post fertilization
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(Supplementary Fig. 7a). dhodh inhibition led to a loss of ventral
melanocytes in stage 38 Xenopus embryos (Supplementary Fig. 7b).
Leflunomide treatment led to an almost complete loss of melanocyte
progenitors at 24 h post fertilization (Fig. 2c), a reduction in the num-
ber of glial cells at 72 h post fertilization (Fig. 2d) and disruption of jaw
cartilage at 72 h post fertilization (data not shown). Leflunomide
reduced the expression of sox10 and dct, which are expressed by neural
crest progenitors and melanocytes, respectively, while leaving other
lineages such as blood and notochord less affected (Supplementary
Fig. 8). Microarray analysis of leflunomide-treated embryos showed
downregulation of 49% of the genes that were upregulated in the 123-
gene melanoma signature, and more than half of these are neural crest
related (see Supplementary Table 2 for the complete list).
The loss of several types of neural crest derivative suggested that
leflunomide acts on neural crest stem cells.We tested leflunomide, and
its derivative A771726, on neural crest stem cells isolated from the fetal
(embryonic day 14.5) rat gut9,10. Both chemicals reduced the number of
self-renewing neural crest stem cells in primary stem cell colonies, to
2765.35% (leflunomide) and 3566.16% (A771726) of control num-
bers (P, 0.0003 and P, 0.00007, respectively, Student’s t-test; Fig. 2e
and Supplementary Fig. 9a). Colony size was also reduced compared
with controls (by 18% and 24%, respectively; P, 0.02, Student’s
t-test), but there was no effect on the differentiation or survival of
specific progeny (Supplementary Fig. 9b, c). These results demonstrate
that DHODH inhibitors negatively regulate the self-renewal of neural
crest stem cells and have an affect on these cells in multiple species.
DHODH catalyses the fourth step in the synthesis of pyrimidine
nucleotides (NTPs)11. We noted striking morphological similarity
between leflunomide-treated embryos and spt5/spt6 mutants12, sug-
gesting that leflunomide acts to suppress transcriptional elongation.
In the spt5sk8 null mutant, we found a lack of both crestin expression
and pigmented melanocytes (similar to leflunomide-treated embryos)
(Supplementary Fig. 10a). At 24 h post fertilization, the gene expression
profiles of spt5sk8 mutants and leflunomide-treated embryos13 were
nearly identical; of 223 genes downregulated after leflunomide treat-
ment, 183 were similarly downregulated in spt5sk8 mutants (Sup-
plementary Table 3 and Supplementary Fig. 10b). These downregu-
lated genes include neural crest genes (crestin, sox10 and mitfa) and
members of the notch pathway (her2 and dlb). We examined the inter-
action of Dhodh with spt5 by incubating the hypomorphic spt5m806
mutant (which has only mild melanocyte defects)14 in low concentra-
tions of leflunomide (3–5mM) and then analysing the number of pig-
mented melanocytes. Enhanced sensitivity to leflunomide was shown
by spt5m806 embryos (Fig. 3a and Supplementary Fig. 11); at 3mM
leflunomide, 99% of mutant embryos had few or no melanocytes,
compared with 0% of wild-type embryos (P5 0.000018, Kruskal–
Wallis test; Supplementary Fig. 11b). These data confirm that
DHODH inhibition affects transcriptional elongation, which is con-
sistent with previous data demonstrating that a reduction in nucleotide
pools in vitro leads to defects in elongation15.
We assessed whether leflunomide specifically caused defects in the
transcriptional elongation of genes required for neural crest develop-
ment by using reverse transcription followed by quantitative PCR (Sup-
plementary Fig. 10c and Supplementary Table 4). Leflunomide caused
either no change or an increase in 59 transcript abundance but a signifi-
cant downregulation of 39 transcripts of mitfa (for 59 transcripts
3.7561.19-fold increase versus 0.3960.07-fold increase for 39 tran-
scripts; P, 0.05, Student’s t-test) and dlb (59 transcripts 1.1360.14-fold
increase versus 39 transcripts 0.7460.07-fold increase; P, 0.05).
Leflunomide did not have a similar effect on control genes such as the
gene encoding b-actin (59 transcripts 1.0360.07-fold increase versus 39
transcripts 0.9960.06-fold increase;P is not significant, Student’s t-test).
In the presence of leflunomide, transcription is initiated normally, but
the transcripts accumulate and do not undergo productive elongation.
To confirm that this mechanism is conserved in human melanoma,
we performed chromatin immunoprecipitation using an antibody
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Figure 1 | Transgenic zebrafishmelanoma andneural crest gene expression.
a, Transgenic zebrafish expressing BRAF(V600E) under the control of the
promoter of the melanocyte-specific gene mitfa, Tg(mitfa:BRAF(V600E)),
develop pigmentation abnormalities andmelanomawhen crossed with p532/2
fish. Their gross embryonic development is largely normal. hpf, hours post
fertilization;WT, wild type. b, Gene expression analysis revealed a unique gene
signature at 72 h post fertilization in theTg(mitfa:BRAF(V600E)); p532/2 strain
(left). Gene set enrichment analysis uncovered an enrichment between the
embryonic gene signature and the adult melanomas that form 4–12 months
later (centre and right; see the Supplementary Information for full protocol
details). Embryo heat-map columns represent an average of three clutches (log2
scale, range22-fold to12-fold increase); adult heat-map columns represent
individual fish (log2 scale, range210-fold to110-fold increase). c, In situ
hybridization of sagittal sections of WT and Tg(mitfa:BRAF(V600E)); p532/2
adults reveal homogeneous crestin expression (blue) only within the dorsal
melanoma; it is absent from normal adult tissues.
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specific for RNA polymerase II (RNA Pol II), followed by sequencing
(ChIP-seq). Transcriptional elongation was measured using the
travelling ratio (TR)16, in which the ratio of RNA Pol II density in
the promoter-proximal region is compared with that in the gene body.
In the human melanoma cell lines A375 and Malme-3M, leflunomide
treatment caused a significant inhibition of transcriptional elongation
(measured as an increase in the TR), particularly for genes with a TR
that was initially low (,7.5). For example, in A375 cells, the TR
increased by .1.3 fold at 21.3% of loci; in Malme-3M cells, this
occurred for 36.3% of loci (Supplementary Table 5). Examination of
RNA Pol II occupancy using metagene analysis at a variety of fold-
change cutoffs (Fig. 3b (A375), Supplementary Fig. 12 (Malme-3M)
and Supplementary Table 5) revealed no defect in transcription ini-
tiation but a decrease in elongation that was pronounced at the 39 end
of genes such as NPM1 and CCND1 (Fig. 3c). Ingenuity Pathway
Analysis on the loci affected in both cell lines revealed a strong enrich-
ment for Myc targets and pathway members17 (Supplementary Fig.
13a, b). Myc, in addition to its requirement for neural crest develop-
ment18, was recently shown to be a potent regulator of transcriptional
pause release in embryonic stem cells16. Our data suggest that the
mechanism by which Myc target genes are regulated at the transcrip-
tional elongation level operates in neural-crest-derived melanoma as
well. Taken together, the genetic and biochemical data demonstrate
that leflunomide acts to modulate transcriptional elongation in both
neural crest development and human melanoma.
Given the effect ofDHODH inhibition onneural crest development,
we tested its effects on melanoma growth. A771726 caused a dose-
dependent decrease in the proliferation of humanmelanoma cell lines
(A375, Hs 294T and RPMI-7951; Fig. 4a). Similarly, a short hairpin
RNA directed against DHODH led to a 57.7% decrease in the pro-
liferation of A375 cells, as well as a decrease in elongation as measured
by ChIP-PCR (Supplementary Fig. 14). Microarray analysis of the
A375 cell line treated with leflunomide revealed downregulation of
genes that are required for neural crest development (such as
SNAI2) and members of the NOTCH pathway (for example, HES6
and JAG1), which is consistent with the effects of leflunomide on
zebrafish embryos (Supplementary Table 6).
Pyrimidine NTP production is regulated at the level of carbamoyl-
phosphate synthetase (CAD)19, the enzyme that is directly upstream of
DHODH. CAD is phosphorylated by the mitogen-activated protein
kinase ERK220, a protein that would be activated in melanoma as a
result of the BRAF(V600E) mutation. We reasoned that combined
blockade of BRAF(V600E) and DHODH would suppress melanoma
growth.Wemeasuredmelanoma cell proliferation after treatment with
the BRAF(V600E) inhibitor PLX4720 (ref. 21) together with A771726
(Fig. 4b, c and Supplementary Fig. 15a, b), and we found that the
combination led to a cooperative suppression of melanoma growth.
WT
Gene body Affected genes
Non-affected
gene
R
an
k 
no
rm
al
iz
ed
co
un
ts
D
M
S
O
DMSO
Le!unomide
DMSO
Le!unomide
Le
!u
no
m
id
e
3 
μm
spt5m806+/– spt5m806–/–a
b c60
290 292 193
NPM1 CCND1 DGAT
–2 kb
5′ 3′
+2 kbDistance from
promoter
Transcription start site
Distance from promoter
M
ea
n 
ra
nk
 n
or
m
al
iz
ed
co
un
ts
Figure 3 | DHODHinhibitionmodulates transcriptional elongation. a, The
hypomorphic spt5m806 homozygous mutant (top right) has only a mild
pigmentation defect compared withWT (top left) or heterozygous (top centre)
animals. Treatment with a low dose of leflunomide (3mM) leads to an almost
complete absence of neural-crest-derived melanocytes in the mutant line. See
Supplementary Fig. 11 for dose–response quantification of this effect.
b, Metagene analysis of RNA Pol II occupancy in A375 humanmelanoma cells
after treatment with leflunomide. The metagene plot allows visualization of all
of the genes that are occupied by RNA Pol II, corrected for individual gene
lengths. Genome-wide RNA Pol II occupancy at the promoter region is
unaffected but is diminished at the 39 end of the genes. The inset shows a higher
magnification of the 39 region of the genes. c, Representative examples of Myc
target genes (NPM1 andCCND1), which demonstrate defects in transcriptional
elongation after treatment with leflunomide. A gene that is minimally affected
(DGAT) is also depicted. ForNPM1, the TR is 5.04 after DMSO treatment and
8.10 after leflunomide treatment. For CCND1, the TR is 3.47 after DMSO
treatment and 4.67 after leflunomide treatment. ForDGAT, the TR is 5.19 after
DMSO treatment and 5.34 after leflunomide treatment.
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Figure 2 | A chemical genetic screen to identify suppressors of neural crest
development. a, A search for chemical suppressors of the crestin1 lineage
during embryogenesis identified NSC210627, a compound that completely
abrogates the expression of crestin (which is normally present in the head, along
the dorsum and in ventrally migrating neural crest cells), as shown by in situ
hybridization (a, left and centre). DMSO is used as a control. The
DiscoveryGate chemoinformatic algorithm revealed structural similarity
between NSC210627 and brequinar (Supplementary Fig. 5), an inhibitor of
DHODH. Leflunomide, a structurally distinct DHODH inhibitor, phenocopies
the crestin phenotype induced by treatment with NSC210627 (a, right).
b–d, Treatment with leflunomide caused an absence of multiple neural crest
derivatives, including pigmented melanocytes (b); melanocyte progenitors,
which were visualized by expressing green fluorescent protein (GFP) under the
control of the mitfa promoter (c); and glial cells, which were visualized by
expressing the fluorescent protein mCherry under the control of the myelin
basic protein (mbp) promoter (d). e, Treatment with leflunomide, or A771726
(Supplementary Fig. 9a), significantly reduced the number of multipotent
daughter cells that could be subcloned from individual primary neural crest
stem cell colonies. Values shown aremean6 s.d. of three replicates; *, P, 0.05
compared with control, Student’s t-test.
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PLX4720 had no effect in non-melanoma cell lines (Supplementary
Fig. 15c, BRAFWT). A771726 demonstrated some antiproliferative
activity in non-melanoma cell lines but was less potent in these cells
than in melanoma cells (Supplementary Fig. 15d).
We examined the in vivo effects of leflunomide and PLX4720 by
using xenografts of A375 cells transplanted into nudemice (Fig. 4c and
Supplementary Fig. 16). At 12 days post treatment, tumours in mice
that had been treated with dimethylsulphoxide (DMSO) as a control
had grown 7.461.3 fold. By contrast, tumours in PLX4720-treated
mice had grown 5.760.16-fold, and those in leflunomide-treatedmice
had grown 4.760.12 fold. The combination of PLX4720 and lefluno-
mide led to an enhanced abrogation of tumour growth, with only
2.260.9 fold growth. In 40%of animals, this combination led to almost
complete tumour regression (PLX4720 and leflunomide versus
PLX4720 alone or leflunomide alone, P, 0.001, analysis of variance
followed by Tukey’s post hoc test). Therefore, we have found that an
inhibitor of embryonic neural crest development, leflunomide, blocks
in vivo tumour growth in combination with the BRAF(V600E) inhi-
bitor PLX4720 when used at clinically meaningful doses.
Our data suggest that inhibition of DHODH abrogates the tran-
scriptional elongation of genes that are required for both neural crest
development and melanoma growth, including Myc target genes and
mitfa. Although DHODH inhibition would be expected to lead to
ubiquitous defects, human mutations in DHODH cause Miller’s syn-
drome22, a craniofacial disorder that is similar to syndromes with
defects in neural crest development. Our data support recent findings
that elongation factors are important for both neural crest develop-
ment23 and cancer growth24. Developmental regulators of transcrip-
tional elongation have recently been identified to be important in
haematopoiesis25, and identification of such factors in the neural crest
awaits further study.
Using chemical genetic approaches in zebrafish andXenopus allows
the identification of molecules that require in vivo contexts for the
expression of relevant phenotypes26. Inhibition of DHODH may be a
unique in vivomechanism for modulating transcriptional elongation.
Leflunomide is a well-tolerated anti-arthritis drug in humans27, and
our data suggest that, for the treatment of melanoma, it would bemost
effective in combination with a BRAF(V600E) inhibitor. This com-
bination therapy may help to overcome resistance to BRAF(V600E)
inhibitors28. As an increasing number of genomic changes are iden-
tified in cancerous cells, the challenge is to target these in concert with
lineage-specific factors to achieve therapeutic synergy. Our approach
to identifying lineage-specific suppressors in zebrafish embryos can be
generalized to other cell types, with direct relevance to human cancer.
METHODS SUMMARY
Microarray analysis was performed on four groups of embryos at 72h post fertiliza-
tion: wild type, Tg(mitfa:BRAF(V600E)), p532/2, and Tg(mitfa:BRAF(V600E));
p532/2 double mutants. Array analysis was also performed for adult
Tg(mitfa:BRAF(V600E)); p532/2melanomas and for adjacent skin. The transcrip-
tional signature of the melanomas was used in gene set enrichment analysis to
identify genes that were significantly enriched in the Tg(mitfa:BRAF
(V600E)); p532/2 embryos. The 123 genes that make up this signature, which is
enriched for markers of the neural crest, were concordantly upregulated or down-
regulated in both BRAF(V600E); p532/2 embryos and tumours. In situ hybridiza-
tion was used to examine the expression of crestin (a pan neural crest marker)
and that of other neural crest genes in embryos (at 24–72 h post fertilization) and
adult tumours. Chemical screening was performed to identify suppressors of the
crestin1 lineage by treating wild-type embryos from 50% epiboly to 24 h post
fertilization with various chemicals, followed by robot-controlled in situ hybrid-
ization. Two inhibitors of DHODHabrogated crestin expression: NSC210627 and
leflunomide. The latter was used for further studies owing to its more widespread
availability. The effect of leflunomide on embryonic neural crest development in
zebrafish was assessed by scoring embryos for melanocytes, iridophores and glial
cells. Leflunomide was further assessed for its ability to affect the multipotent self-
renewal of purified p751a4-integrin
1 rat neural crest stem cells (referred to in the
main text as neural crest stem cells). The effects of leflunomide on transcriptional
elongation in the neural crest were tested using the spt5m806 allele and measuring
pigmentation in response to 3–5 mM leflunomide. Elongation in melanoma cells
was assayed by ChIP-seq using an antibody specific for RNA Pol II andmeasuring
the TR. Leflunomide was tested for anti-melanoma effects on human melanoma
cell lines in the presence or absence of the BRAF(V600E) inhibitor PLX4720. In
vitro proliferation assays were performed using the CellTiter-Glo system
(Promega). In vivo effects were tested by treating established A375 xenografts with
daily intraperitoneal doses of PLX4720 alone, leflunomide alone or both, and the
tumour growth rate was measured on days 4, 7 and 12.
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Figure 4 | Melanoma growth is suppressed by DHODHblockade in concert
with BRAF(V600E) inhibition. a, A771726 causes a dose-dependent decrease
inmelanoma cell proliferation, asmeasured by the CellTiter-Glo assay, in three
human melanoma cell lines that contain the BRAF(V600E) mutation (A375,
Hs 294T and RPMI-7951). b, c, A771726 cooperates with the BRAF(V600E)
inhibitor PLX4720 in inhibiting melanoma cell proliferation in the Hs 294T
(b) and A375 (c) cell lines, as well as other melanoma cell lines (Supplementary
Fig. 15). d, After subcutaneous transplantation of 33 105 A375 cells into nude
mice (n5 4–5), both leflunomide (LEF) alone and PLX4720 alone impair
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